Printed From BioPortfolio.com
AbbVie Announces Another Combination Trial Evaluating New ADC with Bristol-Myers Squibb’s Opdivo
09:51 EDT 22 Sep 2017 | Speciality Pharma Journal
NORTH CHICAGO, Ill. & NEW YORK–(BUSINESS WIRE)–AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie’s investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC). A Phase 1b clinical study is underway that includes evaluating the potential of combining Opdivo, …
Original Article: AbbVie Announces Another Combination Trial Evaluating New ADC with Bristol-Myers Squibb’s Opdivo
